Myelofibrosis is a rare type of bone marrow cancer. In this condition, extensive scarring (fibrosis) occurs in the bone marrow, which keeps the bone marrow from producing the right number of blood ...

Panelists discuss how myelofibrosis progresses from its molecular and genetic origins through various clinical manifestations ...

Ten percent of all cancers are blood cancers, one of which is myelofibrosis that affects about 25,000 people in the United States. There are few drugs approved for treating it. But now ...

Allogeneic hematopoietic stem-cell transplantation is the only curative treatment for myelofibrosis. Driver mutations are the pathophysiological hallmark of the disease, but the role of mutation ...

Myelofibrosis is a rare cancer that affects your bone marrow, the spongy tissue inside some of your bones. In a healthy person, stem cells in the bone marrow make the red blood cells, white blood ...

Ten days of subcutaneous Dacogen resulted in responses among a third of patients with myelofibrosis. Among patients with ...

GSK's cancer unit has been given a fillip by the FDA with a broader-than-expected approval for JAK inhibitor momelotinib for anaemia associated with myelofibrosis, acquired as part of its $1.9 ...

Myelofibrosis can affect people at any age, but it is most often diagnosed in people in their early 70s. Between 10% and 20% of people with myelofibrosis can go on to develop acute myeloid leukaemia.

Around 100,000 Australians live with a rare form of blood cancer, and a new treatment approved by the medicines watchdog is ...

“As a telomerase inhibitor, the potential of imetelstat to affect the malignant clone differentiates it from any other drug currently approved or in development for myelofibrosis treatmen ...